| Title | Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia |
| Authors | Tang, Fei-Fei Huang, Xiao-Jun Zhang, Xiao-Hui Chen, Huan Chen, Yu-Hong Han, Wei Chen, Yao Wang, Feng-Rong Wang, Yu Wang, Jing-Zhi Yan, Chen-Hua Sun, Yu-Qian Mo, Xiao-Dong Liu, Kai-Yan Xu, Lan-Ping |
| Affiliation | Peking Univ, Inst Hematol, Peoples Hosp, 11 Xizhimen South St, Beijing 100044, Peoples R China. Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China. Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China. |
| Keywords | Acute myeloid leukemia Allogeneic hematopoietic cell transplantation Therapy-related MYELODYSPLASTIC SYNDROME SECONDARY THERAPY AML CHEMOTHERAPY GRAFT |
| Issue Date | 2016 |
| Publisher | LEUKEMIA RESEARCH |
| Citation | LEUKEMIA RESEARCH.2016,47,8-15. |
| Abstract | Therapy-related acute myeloid leukemia (T-AML) is associated with poor prognosis after conventional therapy. Allogeneic hematopoietic cell transplantation (allo-HCT) has been proposed as a treatment for T-AML; however, data comparing outcomes of transplants for patients with de novo AML and T-AML are limited. Sixteen adult patients with T-AML during first complete remission after malignant disease received allo-HCT at the Peking University Institute of Hematology between January 1, 2006 and December 31, 2014. Eighty patients with de novo AML were selected using the case-pair method. The 3-year overall survival and leukemia-free survival for T-AML versus de novo AML patients were 66% vs. 79% (P=0.14) and 64% vs. 77% (P=0.13), respectively. The 3-year cumulative non-relapse mortality rates for T-AML versus de novo AML patients were 13% vs. 9% (P=0.47), respectively; the relapse rates were 20% vs. 13% (P=0.25), respectively. Our results suggest that the prognosis of T-AML is comparable to that of de novo AML after transplantation. Although T-AML shows poorer prognosis than de novo AML after conventional therapies, allo-HCT can markedly improve the prognosis of T-AML. (C) 2016. Published by Elsevier Ltd. |
| URI | http://hdl.handle.net/20.500.11897/433549 |
| ISSN | 0145-2126 |
| DOI | 10.1016/j.leukres.2016.05.005 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 医学部待认领 |
